WELIREG + LENVIMA Reduced the Risk of Disease Progression or Death by 30% vs Cabozantinib in Certain Previously Treated Patients With Advanced RCC March 3, 2026
Adjuvant KEYTRUDA + WELIREG Reduced the Risk of Disease Recurrence or Death by 28% vs KEYTRUDA Monotherapy in Certain Patients With Earlier-Stage RCC March 3, 2026
ENHERTU® Supplemental NDA Submitted in Japan as Adjuvant Therapy for Patients with HER2 Positive Early Breast Cancer March 3, 2026
FDA Fast Track Designation for SRN-101 for the Treatment of Recurrent High-Grade Glioma March 3, 2026
FDA tentatively approves AND Application for Lutetium Lu 177 Dotatate (PNT2003) for the treatment of somatostatin receptor-positive GEP-NETs March 3, 2026
